Table of Contents
Table of Contents 3
List of Tables 7
List of Figures 9
AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 10
AbbVie Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 11
AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 12
AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 13
AbbVie Inc, Medical Devices Deals, 2011 to YTD 2017 15
AbbVie Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 16
AbbVie Inc, Pharmaceuticals & Healthcare, Deal Details 23
Asset Purchase 23
AbbVie Acquires Rights of BI-655066 and BI-655064 from Boehringer Ingelheim 23
AbbVie Acquires Active Pharmaceutical Ingredient Manufacturing Facility 24
AbbVie Acquires Rights to Ribasphere from Kadmon 25
Venture Financing 26
Palleon Pharma Raises USD47.6 Million in Series A Financing 26
Disarm Therapeutics Raises USD30 Million in Series A Financing 27
Rodeo Therapeutics Raises USD5.9 Million in Series A Financing 28
eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 30
CARMA Therapeutics Raises Fund through Venture Financing 32
ApoGen Biotech Raises USD7 Million in Series A Financing 33
Artios Pharma Raises USD33.2 Million in Series A Financing 34
Morphic Therapeutic Raises USD51.5 Million in Series A Venture Financing 35
Lodo Therapeutics Raises USD17 Million in Series A Financing 36
Alector Raises USD29.5 Million in Series D Financing 38
Petra Pharma Raises USD48 Million in Series A Financing 40
Effector Therapeutics Raises USD40 Million in Series B Venture Financing 42
Stemcentrx Raises USD500 Million in Financing Round 44
Stemcentrx Raises USD250 Million in Financing Round 45
Stem CentRx Raises more than USD100 Million in Financing Round 46
AM-Pharma Raised USD15.8 Million in Series E Venture Financing 47
Virobay Raises USD8 Million in Extended Series B Financing 49
Kala Pharma Raises Us$22.5 Million In Series B Venture Financing 50
AuraSense Therapeutics Raises Funds Through Extended Series B Financing 52
Avaxia Biologics Raises US$11.4 Million In Series B Financing 53
Alvine Pharmaceuticals Secures USD70 Million in Venture Funding from AbbVie Biotech Ventures 55
Stem CentRx Secures US$23.52 Million In Venture Financing 56
Partnerships 57
AbbVie Enters into Agreement with Alector 57
AbbVie and Harpoon Therapeutics Enter into Research Partnership 58
AbbVie and Turnstone Biologics Enter into Research Agreement 59
AbbVie and Bristol-Myers Squibb Enter into Agreement 60
AbbVie and Principia Biopharma Enter into Agreement 61
Zebra Biologics Enters into Agreement with AbbVie 62
AbbVie Enters into Agreement with Genomics Medicine Ireland and WuXi NextCODE Genomics 63
AbbVie Enters into Research Agreement with Johns Hopkins University School of Medicine 64
AbbVie Enters into Research Agreement with Robert H. Lurie Comprehensive Cancer Center of Northwestern University 65
AbbVie Enters into Agreement with BioArctic 66
X-Chem Enters into Co-Development Agreement with AbbVie 67
AbbVie and Bristol-Myers Squibb Enter into Agreement 68
AbbVie Enters into Research Agreement with University of Chicago 69
Argen-X to Partner with AbbVie 70
Boehringer May Enter into Agreement with AbbVie 71
Myriad Genetics Expands Research Agreement with AbbVie for Veliparib 72
Philogen Enters into R&D Agreement with AbbVie 73
Synlogic Enters into R&D Agreement with AbbVie 74
AbbVie Enters into Co-Development Agreement with University of Texas MD Anderson Cancer Center 75
Enterome Enters into Co-Development Agreement with AbbVie 76
Calico Enters into Co-Development Agreement with AbbVie 77
Seattle Genetics Expands Co-Development Agreement With AbbVie 78
Myriad Genetics Expands Research Agreement with AbbVie 79
AbbVie Expands its Agreement with Galapagos 80
AbbVie Enters Into Co-Development Agreement With Alvine Pharma For ALV003 82
Inventiva Extends Agreement with AbbVie 83
Pharmacyclics Enters Into Co-Development Agreement With National Cancer Institute For PCI-32765 84
Licensing Agreements 86
AbbVie Enters into Licensing Agreement with Pure MHC 86
AbbVie Enters into Licensing Agreement with Dong-A ST 87
AbbVie Enters into Licensing Agreement with CytomX Therapeutics for CD71 88
AbbVie Enters into Licensing Agreement with CytomX Therapeutics 90
AbbVie Enters into Licensing Agreement with Apogenix 92
AbbVie Enters into Licensing Agreement with Life Science Pharma and Seattle Genetics 93
F-star Bio Enters into Licensing agreement with AbbVie 94
Medicines Patent Pool Enters into Licensing Agreement with AbbVie 95
Halozyme Therapeutics Enters into Licensing Agreement with AbbVie 96
AbbVie Enters into License Agreement with C2N Diagnostics for Alzheimer’s Disease Therapy 97
Medicines Patent Pool Enters into Licensing Agreement with AbbVie 98
AbbVie Enters into Licensing Agreement with Kadmon for Ribasphere 99
Receptos Enters Into Licensing Agreement With AbbVie For RPC4046 100
Pharmacyclics Enters Into Licensing Agreement With Novo Nordisk For PCI-27483 101
Abbvie Enters into Licensing Agreement with Reata Pharma 102
Janssen Biotech Enters Into Licensing Agreement With Pharmacyclics For PCI-32765 103
Equity Offering 105
Exicure Raises USD20 Million in Private Placement 105
Aquinnah Pharma Raises USD10 Million in Private Placement of Shares 106
Pharmacyclics Completes Public Offering Of Shares For US$207 Million 107
AbbVie Spin Out from Abbott Laboratories 108
AbbVie Completes IPO 109
Pharmacyclics Files Registration Statement For A Public Offering For US$150 Million 110
Pharmacyclics Completes Private Placement Of Common Stock For US$57 Million 111
Debt Offering 112
AbbVie Raises USD1.48 Billion in Public Offering of 0.38% Notes Due 2019 112
AbbVie Raises USD1.53 Billion in Public Offering of 1.38% Notes Due 2024 113
AbbVie Raises USD795.6 Million in Public Offering of 2.13% Notes Due 2028 114
AbbVie to Raise USD1.8 Billion in Public Offering of 2.3% Notes Due 2021 115
AbbVie to Raise USD1 Billion in Public Offering of 2.85% Notes Due 2023 117
AbbVie to Raise USD2 Billion in Public Offering of 3.2% Notes Due 2026 119
AbbVie to Raise USD1 Billion in Public Offering of 4.3% Notes Due 2036 121
AbbVie to Raise USD2 Billion in Public Offering of 4.45% Notes Due 2046 123
AbbVie Raises USD3 Billion in Public Offering of 1.8% Notes Due 2018 125
AbbVie Raises USD3.75 Billion in Public Offering of 2.5% Notes Due 2020 127
AbbVie Raises USD1 Billion in Public Offering of 3.2% Notes Due 2022 129
AbbVie Raises USD3.75 Billion in Public Offering of 3.6% Notes Due 2025 131
AbbVie Raises USD2.5 Billion in Public Offering of 4.5% Notes Due 2035 133
AbbVie Raises USD2.7 Billion in Public Offering of 4.7% Notes Due 2045 135
AbbVie Raises USD4 Billion in Public Offering of 1.75% Notes Due 2017 137
AbbVie Raises USD1 Billion in Public Offering of 2% Notes Due 2018 138
AbbVie Raises USD3.1 Billion in Public Offering of 2.9% Notes Due 2022 139
AbbVie Raises USD2.6 Billion in Public Offering of 4.4% Notes Due 2042 140
Acquisition 141
AbbVie Acquires Stemcentrx 141
AbbVie Acquires Pharmacyclics 142
AbbVie Acquires ImmuVen from Serra Ventures 144
AbbVie Inc – Key Competitors 145
AbbVie Inc – Key Employees 146
AbbVie Inc – Locations And Subsidiaries 147
Head Office 147
Other Locations & Subsidiaries 147
Recent Developments 155
Financial Announcements 155
Oct 27, 2017: AbbVie Reports Third-Quarter 2017 Financial Results 155
Jul 28, 2017: AbbVie Reports Second-Quarter 2017 Financial Results 157
Apr 27, 2017: AbbVie Reports First-Quarter 2017 Financial Results 159
Jan 27, 2017: AbbVie Reports Full-Year and Fourth-Quarter 2016 Financial Results 161
Oct 28, 2016: AbbVie Reports Third-Quarter 2016 Financial Results 163
Jul 29, 2016: AbbVie Reports Second-Quarter 2016 Financial Results 165
Apr 28, 2016: AbbVie Reports First-Quarter 2016 Financial Results 167
Jan 29, 2016: Abbvie Reports Full-Year 2015 And Fourth-Quarter Financial Results 169
Corporate Communications 171
Jul 31, 2017: AbbVie Announces Delisting from Euronext Paris 171
Feb 11, 2016: Abbvie Launches Scholarship To Support Students Living With Rheumatologic Diseases 172
Government and Public Interest 173
Mar 28, 2017: AbbVie and M2Gen Announce New Collaboration for the Oncology Research Information Exchange Network (ORIEN) Avatar Research Program 173
Product News 174
12/08/2016: European Commission Grants Conditional Marketing Approval for AbbVie’s VENCLYXTO (venetoclax) Monotherapy for Appropriate Patients with Difficult-To-Treat Chronic Lymphocytic Leukaemia 174
12/01/2016: Blood ‘Hot Study’ Shows Potential For Leukaemia Drug 177
10/14/2016: AbbVie Receives CHMP Positive Opinion for VENCLYXTO (venetoclax) Tablets for Appropriate Patients with Difficult-To-Treat Chronic Lymphocytic Leukaemia 178
10/05/2016: AbbVie’s New Oral Therapy VENCLEXTA Now Available For Canadians With A Difficult-To-Treat Blood Cancer 180
07/11/2016: AbbVie Receives U.S. FDA Rare Pediatric Disease Designation for Investigational ABT-414 for the Treatment of a Type of Pediatric Brain Tumor known as Diffuse Intrinsic Pontine Glioma (DIPG) 182
05/18/2016: AbbVie To Present Data on ABT-414 at ASCO 2016 183
04/19/2016: Avella Selected by AbbVie to Distribute Venclexta 184
04/19/2016: Diplomat to Dispense VENCLEXTA for the Treatment of Chronic Lymphocytic Leukemia 185
04/14/2016: Onco360 Chosen for Highly Select VENCLEXTA (VENETOCLAX) Pharmacy Network 186
Jan 19, 2016: Galapagos advances CF clinical development 187
Product Approvals 188
Jan 10, 2017: Australian Approval For Drug That ‘Melts’ Leukaemia 188
Nov 30, 2016: AbbVie Receives Orphan Drug Designation for Investigational IL-23 Inhibitor Risankizumab from the U.S. Food and Drug Administration for the Treatment of Pediatric Patients with Crohns Disease 189
Nov 04, 2016: AbbVie Receives FDA Orphan Drug Designation for Investigational Medicine Veliparib for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer 190
Aug 23, 2016: AbbVie’s Venetoclax Receives EAMS Positive Scientific Opinion in Chronic Lymphocytic Leukaemia from the MHRA in the UK, first in any blood cancer for the scheme 191
Apr 11, 2016: FDA approves new drug for chronic lymphocytic leukemia in patients with a specific chromosomal abnormality 192
Feb 26, 2016: AbbVie Receives EMA Orphan Drug Designation for Investigational Compound Venetoclax for the Treatment of Acute Myeloid Leukemia 193
Jan 28, 2016: Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA for the Combination Treatment of Patients with Untreated Acute Myeloid Leukemia not Eligible for Standard Induction Chemotherapy 194
Jan 20, 2016: Abbvie’s Venetoclax Receives Breakthrough Therapy Designation From FDA In Combination With Rituximab For The Treatment Of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia 195
Jan 12, 2016: U.S. and European Regulators Accept Applications For Abbvie’s Venetoclax, The First Potential BCL-2 Inhibitor For Chronic Lymphocytic Leukemia 196
Clinical Trials 197
Apr 19, 2017: AbbVie Announces Topline Results from Two Phase 3 Studies Investigating Veliparib in Combination with Chemotherapy for the Treatment of Patients with Advanced or Metastatic Squamous Non-Small Cell Lung Cancer and Early-Stage Triple-Negative Breast Cancer 197
Apr 11, 2017: Apogenix Announces Initiation of Clinical Development for ABBV-621 to Treat Solid and Hematologic Tumors by Partner AbbVie 198
Feb 24, 2017: Evaluating A Novel Chemo-free Combination Therapy for Lymphocytic Leukemia 199
Nov 03, 2016: AbbVie to present new data on Venetoclax at the 2016 American Society of Hematology Annual Meeting 200
Nov 03, 2016: Genentech to present data on Venetoclax at American Society of Hematology 2016 Annual Meeting 202
Sep 26, 2016: AbbVie Presents Data on Risankizumab at the 25th European Academy of Dermatology and Venereology Congress 203
Sep 07, 2016: Combination therapy shows promise for chronic myeloid leukemia 204
Aug 12, 2016: Study shows new cancer drug safe and promising for patients with acute myelogenous leukemia 205
Jul 28, 2016: AbbVie Announces Initiation of Phase 3 Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma 206
Jul 08, 2016: Loyola Oncologist Co-authors Veliparib plus Carboplatin Study That Used New, Targeted Model to Test Breast Cancer Treatment 207
Jun 09, 2016: AbbVie Reinforces Commitment to Hematologic Oncology at 21st European Hematology Association Annual Congress Including 10 Abstracts on Investigational Medicine Venetoclax 208
Jun 06, 2016: International Clinical Trial Suggests Value Of Venetoclax Combination Therapy In Patients With B-cell Non-Hodgkin Lymphoma 210
Jun 05, 2016: AbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual Meeting 211
Jun 05, 2016: Results of Phase 1a/1b Study of AbbVies Investigational Medicine Rovalpituzumab Tesirine (Rova-T) Showed Overall Response Rate of 39 Percent in Pretreated Patients with Biomarker-Defined Small Cell Lung Cancer (SCLC) 213
Jun 02, 2016: AbbVie Highlights on Venetoclax (ABT-199) at the Annual European Congress of Rheumatology (EULAR 2016) 214
May 31, 2016: City of Hope Presents Data on Veliparib at The American Society of Clinical Oncology’s Annual Meeting 215
May 24, 2016: IL-23 Inhibitor Risankizumab Induces Remission in Phase II Study in Patients with Moderate-to-Severe Crohn s Disease 217
May 19, 2016: AbbVie To Present Data on Risankizumab at the Digestive Disease Week Annual Meeting 218
May 18, 2016: AbbVie To Present Data on ABBV-399 at ASCO 2016 219
May 18, 2016: AbbVie To Present Data on Veliparib at at ASCO 2016 220
May 18, 2016: AbbVie To Present Data on Venclexta (venetoclax) at ASCO 2016 221
May 16, 2016: AbbVie announces The Lancet Oncology publication of Phase 2 data showing high overall response rates for Venetoclax in patients with relapsed/refractory chronic lymphocytic leukaemia with 17p deletion 222
Feb 10, 2016: AbbVie Announces Positive Top-Line Results From Second Phase 3 Study Investigating Elagolix in Patients with Endometriosis 224
Jan 28, 2016: AbbVie Initiates Enrollment in Phase 3 Clinical Program for Elagolix in Patients with Uterine Fibroids 225
Jan 08, 2016: AbbVie Announces the Launch of Robust Phase 3 Clinical Trial Program Evaluating ABT-494, an Investigational Selective JAK1 Inhibitor, for the Treatment of Rheumatoid Arthritis 226
Appendix 227
Methodology 227
About GlobalData 227
Contact Us 227
Disclaimer 227
AbbVie Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 10
AbbVie Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 11
AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 12
AbbVie Inc, Deals By Therapy Area, 2011 to YTD 2017 13
AbbVie Inc, Medical Devices Deals, 2011 to YTD 2017 15
AbbVie Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 16
AbbVie Acquires Rights of BI-655066 and BI-655064 from Boehringer Ingelheim 23
AbbVie Acquires Active Pharmaceutical Ingredient Manufacturing Facility 24
AbbVie Acquires Rights to Ribasphere from Kadmon 25
Palleon Pharma Raises USD47.6 Million in Series A Financing 26
Disarm Therapeutics Raises USD30 Million in Series A Financing 27
Rodeo Therapeutics Raises USD5.9 Million in Series A Financing 28
eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 30
CARMA Therapeutics Raises Fund through Venture Financing 32
ApoGen Biotech Raises USD7 Million in Series A Financing 33
Artios Pharma Raises USD33.2 Million in Series A Financing 34
Morphic Therapeutic Raises USD51.5 Million in Series A Venture Financing 35
Lodo Therapeutics Raises USD17 Million in Series A Financing 36
Alector Raises USD29.5 Million in Series D Financing 38
Petra Pharma Raises USD48 Million in Series A Financing 40
Effector Therapeutics Raises USD40 Million in Series B Venture Financing 42
Stemcentrx Raises USD500 Million in Financing Round 44
Stemcentrx Raises USD250 Million in Financing Round 45
Stem CentRx Raises more than USD100 Million in Financing Round 46
AM-Pharma Raised USD15.8 Million in Series E Venture Financing 47
Virobay Raises USD8 Million in Extended Series B Financing 49
Kala Pharma Raises Us$22.5 Million In Series B Venture Financing 50
AuraSense Therapeutics Raises Funds Through Extended Series B Financing 52
Avaxia Biologics Raises US$11.4 Million In Series B Financing 53
Alvine Pharmaceuticals Secures USD70 Million in Venture Funding from AbbVie Biotech Ventures 55
Stem CentRx Secures US$23.52 Million In Venture Financing 56
AbbVie Enters into Agreement with Alector 57
AbbVie and Harpoon Therapeutics Enter into Research Partnership 58
AbbVie and Turnstone Biologics Enter into Research Agreement 59
AbbVie and Bristol-Myers Squibb Enter into Agreement 60
AbbVie and Principia Biopharma Enter into Agreement 61
Zebra Biologics Enters into Agreement with AbbVie 62
AbbVie Enters into Agreement with Genomics Medicine Ireland and WuXi NextCODE Genomics 63
AbbVie Enters into Research Agreement with Johns Hopkins University School of Medicine 64
AbbVie Enters into Research Agreement with Robert H. Lurie Comprehensive Cancer Center of Northwestern University 65
AbbVie Enters into Agreement with BioArctic 66
X-Chem Enters into Co-Development Agreement with AbbVie 67
AbbVie and Bristol-Myers Squibb Enter into Agreement 68
AbbVie Enters into Research Agreement with University of Chicago 69
Argen-X to Partner with AbbVie 70
Boehringer May Enter into Agreement with AbbVie 71
Myriad Genetics Expands Research Agreement with AbbVie for Veliparib 72
Philogen Enters into R&D Agreement with AbbVie 73
Synlogic Enters into R&D Agreement with AbbVie 74
AbbVie Enters into Co-Development Agreement with University of Texas MD Anderson Cancer Center 75
Enterome Enters into Co-Development Agreement with AbbVie 76
Calico Enters into Co-Development Agreement with AbbVie 77
Seattle Genetics Expands Co-Development Agreement With AbbVie 78
Myriad Genetics Expands Research Agreement with AbbVie 79
AbbVie Expands its Agreement with Galapagos 80
AbbVie Enters Into Co-Development Agreement With Alvine Pharma For ALV003 82
Inventiva Extends Agreement with AbbVie 83
Pharmacyclics Enters Into Co-Development Agreement With National Cancer Institute For PCI-32765 84
AbbVie Enters into Licensing Agreement with Pure MHC 86
AbbVie Enters into Licensing Agreement with Dong-A ST 87
AbbVie Enters into Licensing Agreement with CytomX Therapeutics for CD71 88
AbbVie Enters into Licensing Agreement with CytomX Therapeutics 90
AbbVie Enters into Licensing Agreement with Apogenix 92
AbbVie Enters into Licensing Agreement with Life Science Pharma and Seattle Genetics 93
F-star Bio Enters into Licensing agreement with AbbVie 94
Medicines Patent Pool Enters into Licensing Agreement with AbbVie 95
Halozyme Therapeutics Enters into Licensing Agreement with AbbVie 96
AbbVie Enters into License Agreement with C2N Diagnostics for Alzheimer’s Disease Therapy 97
Medicines Patent Pool Enters into Licensing Agreement with AbbVie 98
AbbVie Enters into Licensing Agreement with Kadmon for Ribasphere 99
Receptos Enters Into Licensing Agreement With AbbVie For RPC4046 100
Pharmacyclics Enters Into Licensing Agreement With Novo Nordisk For PCI-27483 101
Abbvie Enters into Licensing Agreement with Reata Pharma 102
Janssen Biotech Enters Into Licensing Agreement With Pharmacyclics For PCI-32765 103
Exicure Raises USD20 Million in Private Placement 105
Aquinnah Pharma Raises USD10 Million in Private Placement of Shares 106
Pharmacyclics Completes Public Offering Of Shares For US$207 Million 107
AbbVie Spin Out from Abbott Laboratories 108
AbbVie Completes IPO 109
Pharmacyclics Files Registration Statement For A Public Offering For US$150 Million 110
Pharmacyclics Completes Private Placement Of Common Stock For US$57 Million 111
AbbVie Raises USD1.48 Billion in Public Offering of 0.38% Notes Due 2019 112
AbbVie Raises USD1.53 Billion in Public Offering of 1.38% Notes Due 2024 113
AbbVie Raises USD795.6 Million in Public Offering of 2.13% Notes Due 2028 114
AbbVie to Raise USD1.8 Billion in Public Offering of 2.3% Notes Due 2021 115
AbbVie to Raise USD1 Billion in Public Offering of 2.85% Notes Due 2023 117
AbbVie to Raise USD2 Billion in Public Offering of 3.2% Notes Due 2026 119
AbbVie to Raise USD1 Billion in Public Offering of 4.3% Notes Due 2036 121
AbbVie to Raise USD2 Billion in Public Offering of 4.45% Notes Due 2046 123
AbbVie Raises USD3 Billion in Public Offering of 1.8% Notes Due 2018 125
AbbVie Raises USD3.75 Billion in Public Offering of 2.5% Notes Due 2020 127
AbbVie Raises USD1 Billion in Public Offering of 3.2% Notes Due 2022 129
AbbVie Raises USD3.75 Billion in Public Offering of 3.6% Notes Due 2025 131
AbbVie Raises USD2.5 Billion in Public Offering of 4.5% Notes Due 2035 133
AbbVie Raises USD2.7 Billion in Public Offering of 4.7% Notes Due 2045 135
AbbVie Raises USD4 Billion in Public Offering of 1.75% Notes Due 2017 137
AbbVie Raises USD1 Billion in Public Offering of 2% Notes Due 2018 138
AbbVie Raises USD3.1 Billion in Public Offering of 2.9% Notes Due 2022 139
AbbVie Raises USD2.6 Billion in Public Offering of 4.4% Notes Due 2042 140
AbbVie Acquires Stemcentrx 141
AbbVie Acquires Pharmacyclics 142
AbbVie Acquires ImmuVen from Serra Ventures 144
AbbVie Inc, Key Competitors 145
AbbVie Inc, Key Employees 146
AbbVie Inc, Subsidiaries 147
